Milestone Scientific Receives China's FDA Approval For The Wand® Handpiece

LIVINGSTON, NJ--(Marketwired - May 08, 2014) - Milestone Scientific Inc. (MLSS), a leading medical research and development company that designs and patents innovative injection technology, today announced that the State Food and Drug Administration (SFDA) of the People's Republic of China has approved Milestone's The Wand® handpiece. This approval follows prior approval by China's SFDA of Milestone's STA Single Tooth Anesthesia System®computer (STA System). The SFDA had bifurcated approval of the STA Systemcomputer and The Wand® handpiece.

Leonard Osser, Chief Executive Officer of Milestone Scientific commented, "At long last, our STA System and The Wand handpiece have been granted registration approval by the State Food and Drug Administration of the People's Republic of China and we now have all necessary approvals to commence sales in China. We look forward to pursuing the Chinese market."

The patented, award-winning STA System is a computer-controlled, pressure-sensitive injection system, which provides dentists with audible and visual signals as to in-tissue pressure and needle location. Milestone's latest achievement in computer-controlled local anesthesia delivery makes the injection process more comfortable for both dentists and patients and allows for the painless delivery of local anesthetic. In addition to its general use for all dental injections, the STA System is uniquely capable of predictably and more comfortably administering "Single Tooth Anesthesia" into the Periodontal Intraligamentary (PDL) space. This injection results in the patient having no collateral numbness and no pain along with instant, predictable anesthesia. The benefit of this injection with the STAinstrument is significant for the patient, the dentist and the business of dentistry.

About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:
Investor Relations:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

Help employers find you! Check out all the jobs and post your resume.